Print
Email
Natus Medical Inc. (BABY) filed Quarterly Report for the period ended 2011-09-30.
Natus Medical Inc. has a market cap of $244.16 million; its shares were traded at around $8.33 with a P/E ratio of 14.61 and P/S ratio of 1.12. Natus Medical Inc. had an annual average earning growth of 10.2% over the past 5 years.
This is the annual revenues and earnings per share of BABY over the last 10 years. For detailed 10-year financial data and charts, go to 10-Year Financials of BABY.
Highlight of Business Operations:
Our business and operating results have been and will continue to be affected by worldwide economic conditions. Our sales are dependent on both capital spending by hospitals and foreign health ministries. As a result of economic trends, our revenue decreased 3% to $51.3 million in the third quarter ended September 30, 2011, compared to $53.2 million in the comparable quarter of the previous year. Net income decreased to $154,000, or $0.01 per diluted share, for the third quarter of 2011 compared with net income of $3.6 million, or $0.12 per diluted share, for the third quarter of 2010. We completed the acquisition of Embla LLC in September of 2011. Medix and Embla contributed $6.1 million to our third quarter revenue, while revenue from our existing product lines decreased 14% in the 2011 period.Revenue from devices and systems increased 1.7% to $31.1 million in the three months ended September 30, 2011, compared to $30.6 million in the same period in 2010. Medix and Embla contributed $3.5 million of device and system revenue during the 2011 quarter. Devices and systems revenue from our neurology and other diagnostic products other than Embla decreased $900,000 or 5% to $15.9 million and devices and systems revenue from newborn hearing screening and newborn care revenue other than Medix decreased $2.1 million. Revenue from devices and systems was 61% of total revenue in the three months ended September 30, 2011 compared to 58% of total revenue for the third quarter of 2010.
Revenue from supplies and services decreased $2.4 million, or 11%, to $19.2 million in the third quarter of 2011 compared to $21.6 million in the same period in 2010. Medix and Embla contributed $2.6 million of supplies and services revenue in the third quarter of 2011. Revenue from hearing supplies decreased by $2.1 million and revenue from service fees and newborn care supplies other than Medix decreased by $500,000, while revenue from neurology supplies other than Embla decreased by $2.4 million. Revenue from supplies and services was 37% of total revenue in the three months ended September 30, 2011 compared to 41% of total revenue for the third quarter of 2010.
Revenue from device and systems increased $12.7 million, or 13%, to $107.2 million in the nine months ended September 30, 2011 compared to $94.5 million in the same period in 2010. Medix and Embla contributed $13.3 million of devices and systems revenue in the 2011 period. Revenue from our other neurology products increased by $4.3 million during the 2011 period and revenue from our diagnostic sleep and balance monitoring products increased by $2.3 million. These increases were offset by a $7.2 million decrease in revenue from our other product lines including newborn hearing screening and other newborn care products other than Medix. Revenue from devices and systems was 64% of consolidated revenue in the nine months ended September 30, 2011 compared to 61% of consolidated revenue for the first nine months of 2010.
Gross profit as a percentage of revenue was 57% for the nine months ended September 30, 2011 compared to 60% for the respective period in 2010, reflecting sales mix towards lower margin products coupled with Medix products having lower margins than our other product lines. Cost of revenue increased $10.5 million, or 17%, to $73.2 million in the nine months ended September 30, 2011, from $62.7 million in 2010 as a result of increased sales. Gross profit increased $2.6 million, or 3%, to $95.4 million in 2011 from $92.8 million in 2010.
Subscribe RSS
